AS1411-functionalized albumin nanoparticles for nucleolin-targeted realgar delivery and therapy in triple-negative breast cancer
Frontiers in Pharmacology · 29.07.2026 · 17
DOI: 10.3389/fphar.2026.1891302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.07.2026. Verfasst von Liping Dong und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Changsha Medical University, ChangSha, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Education Department of Hunan Province.
Abstract (Originalsprache)
Realgar (As 4 S 4 ) has shown antitumor activity, but its pharmaceutical application is limited by poor aqueous solubility, low bioavailability, and systemic toxicity. In this study, we developed AS1411-functionalized albumin nanoparticles (As 4 S 4 @ BSA-AS1411 NPs) for targeted delivery of realgar to triple-negative breast cancer (TNBC). Bulk As 4 S 4 was converted into nanosized clusters and encapsulated in a bovine serum albumin (BSA) matrix, followed by surface conjugation with the nucleolin-targeting aptamer AS1411. The resulting nanoparticles showed suitable physicochemical properties and good colloidal stability in physiologically relevant media, together with enhanced cellular internalization in 4T1 cells. Compared with non-targeted nanoparticles, AS1411 modification significantly increased cytotoxicity and reduced the migratory ability of 4T1 cells. Mechanistic studies showed that treatment with As 4 S 4 @BSA-AS1411 NPs was associated with upregulation of GADD45G and downregulation of mTOR, suggesting a stress-related antiproliferative effect. In vivo fluorescence imaging demonstrated increased tumor accumulation of AS1411-functionalized NPs. In 4T1 tumor-bearing mice, systemic administration of As 4 S 4 @BSA-AS1411 NPs produced greater tumor growth inhibition than non-targeted controls, accompanied by increased apoptosis and reduced proliferative activity in tumor tissues. In addition, the formulation showed good in vivo tolerability, with no evident systemic toxicity or hemolytic activity. These findings indicate that AS1411-functionalized albumin NPs are a promising delivery system for improving the antitumor efficacy and safety profile of realgar in TNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Nursing, Changsha Medical University, ChangSha, China.
- Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, ChangSha, China.
- Department of Laboratory Medicine, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- Education Department of Hunan Province
Zitieren
APA
Dong, L., Ran, W., Li, Y., Yang, L., & Zhou, X. (2026). AS1411-functionalized albumin nanoparticles for nucleolin-targeted realgar delivery and therapy in triple-negative breast cancer. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1891302
Vancouver
Dong L, Ran W, Li Y, Yang L, Zhou X. AS1411-functionalized albumin nanoparticles for nucleolin-targeted realgar delivery and therapy in triple-negative breast cancer. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1891302
BibTeX
@article{Dong2026,
author = {Dong, Liping and Ran, Wenzhuo and Li, Yanqiong and Yang, Lixia and Zhou, Xi},
title = {AS1411-functionalized albumin nanoparticles for nucleolin-targeted realgar delivery and therapy in triple-negative breast cancer},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1891302}
}
EUVIMED